Genotyping for PPAR-Agonist Edema Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments with PPAR-agonists often lead to dose-dependent peripheral edema due to unknown mechanisms, with genetic polymorphisms potentially predisposing individuals to increased risk, necessitating a method to identify susceptible individuals and tailor treatment regimens.
Innovation Solution
Development of nucleic acid molecules and allele-specific oligonucleotides targeting specific single nucleotide polymorphisms in the renin, endothelin-1, and β1-adrenergic receptor genes to predict susceptibility to PPAR-agonist-induced edema, allowing for personalized treatment approaches.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PPAR-agonists are administered to treat metabolic conditions, then therapeutic efficacy is improved, but dose-dependent peripheral edema occurs as a harmful side effect
Solution Approach 1:
The patent applies preliminary action by genotyping patients for specific polymorphisms (such as ADRB1 Arg389Gly) before administering PPAR-agonists. This pre-screening identifies individuals at high risk for developing peripheral edema, allowing clinicians to select alternative treatments or adjust dosing regimens in advance, thereby preventing the harmful side effect before it occurs while preserving therapeutic efficacy for suitable candidates
Solution Approach 2:
The patent applies local quality by differentiating patient populations based on their genetic characteristics. Instead of a uniform treatment approach, the method tailors therapy selection to specific genetic subgroups - patients with certain polymorphisms receive alternative treatments while those without these polymorphisms can receive PPAR-agonists. This localized treatment strategy maintains high therapeutic efficacy overall while minimizing edema occurrence in vulnerable subgroups
2Ease of operation
If standard PPAR-agonist treatment regimens are used, then treatment simplicity is maintained, but individual variability in edema susceptibility increases risk
Solution Approach 1:
The patent applies parameter changes by introducing a genetic parameter (polymorphism status) into the treatment decision-making process. Rather than relying solely on clinical judgment and trial-and-error, the method uses objective genetic markers (such as ADRB1 Arg389Gly polymorphism) to stratify patients into risk categories. This transforms the treatment approach from subjective and variable to objective and predictable, while adding only a minimal genotyping step to the overall process
Data Source
AI summary
The invention provides novel polynucleotides and polypeptides associated with the incidence of PPAR-agonist induced edema. The invention also provides polynucleotide fragments corresponding to the genomic and/or coding regions of these polynucleotides which comprise at least one polymorphic locus per fragment. Allele-specific primers and probes which hybridize to these regions, and/or which comprise at least one polymorphic locus are also provided. The polynucleotides, primers, and probes of the present invention are useful in phenotype correlations, medicine, and genetic analysis. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel polynucleotides and polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders, particularly PPAR-agonist induced edema or related indications. The invention further relates to screening methods for identifying agonists of PPAR proteins with decreased risk of inducing peripheral edema in patients.